Unauthorised or falsified medicinal products carry considerable risks particularly if they contain undeclared substances, impurities or incorrect doses
But because the FDA hasn't approved GLP-1s as an addiction treatment, insurance companies often won't pay for them when prescribed for addiction, keeping them out of reach for some patients who might benefit
The FDA has responded with three waves of enforcement letters - September 2025, March 2026, and June 2026 - targeting telehealth companies for misleading GLP-1 marketing
The Big Trial of a GLP-1 drug (Wegovy) to Reduce Major Cardiovascular Events Presented at the American Heart Association and simultaneously published in NEJM today is the trial of over 17,600 patients who were randomly assigned either the GLP-1 semaglutide (a glucagon-like peptide-1 receptor agonist) or placebo and were followed for well over 3 years
HEK-GLP-1R cells (A and B) or INS-1E cells (C and D) were challenged for 5 min with either vehicle (1% v/v DMSO), GLP-1 936 amide (1 or 10 M as indicated) or compound 2 alone or GLP-1 936 amide (1 M) and compound 2 together as indicated
Get it all for just $95/month, medication, consultation and shipping included.
